Clinical Trials
Clinical Trials
RESIN
Real-world data from RESiN support evidence on the efficacy and safety of SIRT with
SIR-Spheres® Y-90 resin microspheres
Results from the mCRC cohort
Abbreviations:
HCC: Hepatocellular carcinoma ; mCRC: metastatic colorectal cancer ; ECOG PS: Eastern Cooperative Oncology Group - Performance Status ; SBRT: Stereotactic Body Radiation Therapy ; PVE: Portal vein embolization ; BSA : Body surface area ; OS: Overall survival ; PFS: Progression-free survival ; BCLC: Barcelona clinic liver cancer ;
References:
- Sirtex Press Release Aug 2020. https://appliedradiationoncology.com/articles/sirtex-completes-u-s-resin-registry-enrollment. Last access: Aug 12th 2021. 2. Frantz S et al. J Vasc Interv Radiol 2021; 32: 845–852. 3. Brown D et al. J Gastrointest Oncol 2021; 12(2):639-657. 4. Emmons et al. Radiol 2022; doi: 10.1148/radiol.220387.
Indications for Use: SIR-Spheres Y-90 resin microspheres are indicated for the treatment of unresectable metastatic liver tumors from primary colorectal cancer with adjuvant intrahepatic artery chemotherapy (IHAC) of FUDR (Floxuridine). Consult the Instructions for Use for a complete listing of indications, contraindications, side effects, warnings, and precautions.